Boundless Bio, Inc Common Stock
Yahoo Finance • 4 days ago
Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment
(RTTNews) - Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and... Full story
Yahoo Finance • 5 days ago
These Emerging Companies Are Racing Toward Major Catalysts
DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies tha... Full story
Yahoo Finance • 6 days ago
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking ca... Full story
Yahoo Finance • 2 months ago
Boundless Bio GAAP EPS of -$0.60
* Boundless Bio press release [https://seekingalpha.com/pr/20507515-boundless-bio-reports-first-quarter-2026-financial-results-and-business-highlights] (BOLD [https://seekingalpha.com/symbol/BOLD]): Q1 GAAP EPS of -$0.60. * Cash Positi... Full story
Yahoo Finance • 4 months ago
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story
Yahoo Finance • 8 months ago
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable o... Full story
Yahoo Finance • 11 months ago
Boundless Bio (BOLD) Q2 R&D Drops 17%
Key Points Research and development expenses were $12.2 million for the second quarter of 2025, compared to $14.7 million in the same period of 2024. Cash, cash equivalents, and short-term investments totaled $127.1 million as of June 30,... Full story
Yahoo Finance • last year
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable o... Full story
Yahoo Finance • last year
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-... Full story
Yahoo Finance • last year
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable... Full story
Yahoo Finance • last year
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable o... Full story
Yahoo Finance • 2 years ago
Insiders are Amassing These 10 Stocks in April
In this article, we will take a detailed look at Insiders are Amassing These 10 Stocks in April. For a quick overview of such stocks, read our article Insiders are Amassing These 5 Stocks in April. Can I make money investing in stocks tha... Full story